Current Treatment Options in Gastroenterology

, Volume 10, Issue 3, pp 171–177

Efficacy of infliximab for luminal and fistulizing Crohn’s disease and in ulcerative colitis

Article

Opinion statement

Infliximab is arguably the first major advance in therapy for inflammatory bowel disease in more than a quarter of a century. Although it is important to distinguish efficacy from effectiveness, the data from clinical practice mirror those from randomized controlled trials. Infliximab has proven efficacious for luminal manifestations of Crohn’s disease (CD) regardless of location. It also has proven efficacy in the subset of penetrating disease to the skin and perianal area, and it increases rates of steroid-free remission. These benefits are reflected in improved quality of life, with limited data showing that infliximab can decrease rates of hospitalization and CD-related surgery. Infliximab also has proven to be efficacious in patients with ulcerative colitis (UC) and has increased rates of steroid-free remission. Whether infliximab will have an impact on the risk of colorectal cancer in UC and Crohn’s colitis has yet to be determined. The combination of strong evidence from large randomized controlled trials with substantial examination of use in the practice setting has moved biologic therapy with infliximab from novel to mainstream. In this review, the data for the efficacy of infliximab in controlled trials will be discussed in the context of real world effectiveness.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Bamias G, Nyce MR, De La Rue SA, et al.: New concepts in the pathophysiology of inflammatory bowel disease. Ann Intern Med 2005, 143:895–904.PubMedGoogle Scholar
  2. 2.
    Farrell RJ, Shah SA, Lodhavia PJ, et al.: Clinical experience with infliximab therapy in 100 patients with Crohn’s disease. Am J Gastroenterol 2000, 95:3490–3497.PubMedCrossRefGoogle Scholar
  3. 3.
    Cohen RD: Efficacy and safety of repeated infliximab infusions for Crohn’s disease: 1-year clinical experience. Inflamm Bowel Dis 2001, 7(Suppl 1):S17–S22.PubMedCrossRefGoogle Scholar
  4. 4.
    Ricart E, Panaccione R, Loftus EV, et al.: Infliximab for Crohn’s disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001, 96:722–729.PubMedCrossRefGoogle Scholar
  5. 5.
    Lichtenstein G, Cohen RD, Feagan BG, et al.: Safety of infliximab in Crohn’s disease: data from the 5000 — patient TREAT registry [abstract]. Gastroenterology 2004, 126:A54.Google Scholar
  6. 6.
    Gasche C, Scholmerich J, Brynskov J, et al.: A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000, 6:8–15.PubMedCrossRefGoogle Scholar
  7. 7.
    ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ: Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease. Gut 2002, 50:206–211.PubMedCrossRefGoogle Scholar
  8. 8.
    Van den Brande JM, Braat H, van den Brink GR, et al.: Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology 2003, 124:1774–1785.PubMedCrossRefGoogle Scholar
  9. 9.
    Zimmermann-Nielsen E, Agnholt J, Thorlacius-Ussing O, et al.: Complement activation in plasma before and after infliximab treatment in Crohn disease. Scand J Gastroenterol 2003, 38:1050–1054.PubMedCrossRefGoogle Scholar
  10. 10.
    Akobeng AK, Zachos M: Tumor necrosis factor-alpha antibody for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2004, 1:CD003574.Google Scholar
  11. 11.
    Lichtenstein GR, Yan S, Bala M, et al.: Remission in patients with Crohn’s disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004, 99:91–96.PubMedCrossRefGoogle Scholar
  12. 12.
    Lichtenstein GR, Abreu MT, Cohen R, et al.: American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006, 130:940–987.PubMedCrossRefGoogle Scholar
  13. 13.
    Targan SR, Hanauer SB, van Deventer SJ, et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997, 337:1029–1035.PubMedCrossRefGoogle Scholar
  14. 14.
    Ljung T, Karlen P, Schmidt D, et al.: Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004, 53:849–853.PubMedCrossRefGoogle Scholar
  15. 15.
    Hanauer SB, Feagan BG, Lichtenstein GR, et al.: Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002, 359:1541–1549.PubMedCrossRefGoogle Scholar
  16. 16.
    Baert F, Noman M, Vermeire S, et al.: Influence of immuno-genicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003, 348:601–608.PubMedCrossRefGoogle Scholar
  17. 17.
    Mahadevan U, Kane S, Sandborn WJ, et al.: Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn’s disease. Aliment Pharmacol Ther 2005, 21:733–738.PubMedCrossRefGoogle Scholar
  18. 18.
    Vasiliauskas EA, Church JA, Silverman N, et al.: Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006, 4:1255–1258.PubMedCrossRefGoogle Scholar
  19. 19.
    Centers for Disease Control and Prevention. The immuno-compromised traveler. Travelers’ Health: Yellow Book [serial online]. http://www2.ncid.cdc.gov/travel/yb/utils/ybGet.asp?section=special&obj=hivtrav.htm. Accessed February 27, 2007.Google Scholar
  20. 20.
    Rutgeerts P, D’Haens G, Targan S, et al.: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999, 117:761–769.PubMedCrossRefGoogle Scholar
  21. 21.
    Rutgeerts P, Feagan BG, Lichtenstein GR, et al.: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 2004, 126:402–413.PubMedCrossRefGoogle Scholar
  22. 22.
    Biancone L, Orlando A, Kohn A, et al.: Infliximab and newly diagnosed neoplasia in Crohn’s disease: a multicentre matched pair study. Gut 2006, 55:228–233.PubMedCrossRefGoogle Scholar
  23. 23.
    Thayu M, Markowitz JE, Mamula P, et al.: Hepatosplenic T-cell lymphoma in an adolescent patient after immuno-modulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 2005, 40:220–222.PubMedCrossRefGoogle Scholar
  24. 24.
    Lichtenstein GR, Feagan BG, Cohen RD, et al.: Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol 2006, 4:621–630.PubMedCrossRefGoogle Scholar
  25. 25.
    Farrell RJ, Alsahli M, Jeen YT, et al.: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology 2003, 124:917–924.PubMedCrossRefGoogle Scholar
  26. 26.
    Hommes D, Baert F, van Assche C, et al.: Management of recent onset Crohn’s disease — a controlled randomized trial comparing step-up and top-down therapy [abstract]. Gastroenterology 2005, 129:371.CrossRefGoogle Scholar
  27. 27.
    Rubenstein JH, Chong RY, Cohen RD: Infliximab decreases resource use among patients with Crohn’s disease. J Clin Gastroenterol 2002, 35:151–156.PubMedCrossRefGoogle Scholar
  28. 28.
    Sands BE, Anderson FH, Bernstein CN, et al.: Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004, 350:876–885.PubMedCrossRefGoogle Scholar
  29. 29.
    Levy C, Tremaine WJ: Management of internal fistulas in Crohn’s disease. Inflamm Bowel Dis 2002, 8:106–111.PubMedCrossRefGoogle Scholar
  30. 30.
    Arseneau KO, Cohn SM, Cominelli F, et al.: Cost-utility of initial medical management for Crohn’s disease perianal fistulae. Gastroenterology 2001, 120:1640–1656.PubMedCrossRefGoogle Scholar
  31. 31.
    Lawson MM, Thomas AG, Akobeng AK: Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006, 3:CD005112.Google Scholar
  32. 32.
    Rutgeerts P, Sandborn WJ, Feagan BG, et al.: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462–2476.PubMedCrossRefGoogle Scholar
  33. 33.
    Jarnerot G, Hertervig E, Friis-Liby I, et al.: Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005, 128:1805–1811.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.University of Virginia Digestive Health Center of ExcellenceCharlottesvilleUSA

Personalised recommendations